Conditions: Hepatitis C
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 40
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C

Detailed description:

Arms:
arm 1: 25 mg b.i.d. MK7009 arm 2: 75 mg b.i.d. MK7009 arm 3: 250 mg b.i.d. MK7009 arm 4: 500 mg b.i.d. MK7009 arm 5: 700 mg b.i.d. MK7009 arm 6: 125 mg q.d. MK7009 arm 7: 600 mg q.d. MK7009 arm 8: Placebo

Interventions: intervention 1: Comparator: MK7009 intervention 2: Comparator: Placebo
Intervention descriptions: intervention 1: Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8. intervention 2: MK7009 Placebo

Protocol document: